baxdrostat safety, tolerability, pharmacokinetic and pharmacodynamic study in a Japanese population

Study identifier:CIN-107-126

ClinicalTrials.gov identifier:NCT05966324

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1 Single and Multiple Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Baxdrostat in Healthy Japanese and Caucasian Subjects

Medical condition

hypertension

Phase

Phase 1

Healthy volunteers

Yes

Study drug

baxdrostat

Sex

All

Actual Enrollment

41

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 05 Jul 2022
Primary Completion Date: 20 Sept 2022
Study Completion Date: 20 Sept 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria